drugset / Trial / NCT02234739

Summary

voriconazole is recommended as first-line therapy for invasive pulmonary aspergillosis, however the efficacy and safety of voriconazole for treating invasive pulmonary aspergillosis secondary to COPD is not clear. This study aims to investigate the effectiveness and tolerability of intravenous voriconazole for treatment of invasive pulmonary aspergillosis in Chinese patients with COPD, by monitoring changes in clinical symptoms, eradication of aspergillus, improvement of chest imaging as well as record of possible adverse reactions following 2-week intravenous instillation of voriconazole.

Timeline

Start
2014-10
Primary completion
2016-10
Completion
2016-12

Drugs

EvaluationDrugModalityDoseRoute
Subject Voriconazole Small molecule Intravenous